About Kawin
POSITION：Home>News
-
-
2020-11-26Class 1 Innovative Drug Coblopasvir Hydrochloride Capsules Launched for Treatment of Hepati
11 February 2020, Kawin Technology's therapeutic drug of chronic hepatitis C virus (HCV) , Coblopasvir Hydrochloride Capsule (trade name: 凱力唯 ), was approved by National Medical Products Administration through priority review and approval process. This pr...
Details
-
-
-
2020-11-26賽波唯? (Sofosbuvir Tablets) Approved for HCV Treatment
18 March 2020, Kawin Technology's 賽波唯 (Sofosbuvir Tablets) was approved by National Medical Products Administration as the first domestically approved NS5B polymerase inhibitor. 賽波唯 combined with Kawin's newly approved Class 1 innovative drug, NS5A inhibi...
Details
-
-
-
2020-11-26Many products and dosage forms received GMP re-certification
August 8, 2018, Kawin Technology's Recombinant Human Interferon 2b Vaginal Effervescent Tablets, Peginterferon -2 Injection, Recombinant Human Interferon 2b Injection, Lyophilized Powder for Injection, Small Volume Parenteral Solutions, received Certifica...
Details
-
-
-
2018-03-21Dr. Zhou Desheng, Chairman of Kawin Technology, Interviewed by Beijing TV
On March 20th, 2018, Beijing TV Morning Beijing aired a special interview, themed as high-end drug for China and better quality of life, with Dr. Zhou Desheng, Chairman of Kawin Technology. Kawin Technology has been always pursuing a mission of innovation...
Details
-
